Weight-loss drug retatrutide shows up to 25% weight reduction

Summarised from 4 outlets · Updated 2 Oct, 11:56 · Archive

Retatrutide, an experimental drug targeting three gut hormones, helped people lose up to 25% of body weight in trials.

Retatrutide is an experimental weight-loss drug that mimics three key gut hormones: GLP-1, GIP and glucagon. These hormones help control appetite, blood sugar and metabolism. Unlike existing drugs such as Wegovy, which targets only the GLP-1 pathway, or Mounjaro, which targets GLP-1 plus GIP, retatrutide targets all three hormones.

In the largest study of its kind, trial participants lost up to 25% of their body weight. Even at the lowest dose, patients lost 12.7% of their weight. The drug also appeared to improve blood sugar levels and reduce inflammation, though it has not yet been approved by any regulatory agency.

The New York Post reports that retatrutide is nearing the end of clinical trials and is expected to be submitted to the FDA for approval early next year.

How it is being reported

• ‘Triple-G’ weight loss drug update: Even on the lowest dose, trial patients lost 12.7% of their weightThe drug, the first of its kind to target three metabolic receptors (GLP-1, GIP, and glucagon), is nearing the end of clinical trials and is expected to be submitted to the FDA for approval early next year.New York Post · 1 Oct, 15:18
• Experimental weight loss drug yields big results, but not yet FDA approvedRetatrutide is the latest experimental weight-loss drug with promising clinical trial results, but it's not yet approved by the FDA. Dr. Céline Gounder has the latest.CBS News · 30 Sept, 14:44
• Most powerful obesity drug yet: People lost up to 25% of weight in trialRetatrutide is a triple-hormone obesity drug simulating GLP-1, GIP, and glucagon.Ars Technica · 29 Sept, 23:30
• ‘Godzilla’ of weight-loss drugs could provide other important health benefitsThough not yet approved by any regulatory agency, retatrutide could help improve blood sugar levels and reduce inflammation The ‘Godzilla’ of weight-loss drugs could help improve blood sugar levels, reduce inflammation and cut a person’s body weight by a quarter, according to the largest study of its kind. Retatrutide mimics three key gut hormones that help control appetite, blood sugar and metabolism: GLP-1, GIP and glucagon. Unlike other drugs such as Wegovy, which primarily targets the GLP-1 pathway to suppress appetite, or Mounjaro, which contains GLP-1 plus GIP to control blood sugar…The Guardian · 29 Sept, 23:01

In this story: retatrutide · FDA · Wegovy · Mounjaro

This summary was written by AI from the headlines and standfirsts above, and states as fact only what at least two outlets report. How we use AI · Report a problem · Corrections log